{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:44:05Z","timestamp":1789753445912,"version":"4.0.1"},"reference-count":52,"publisher":"MIT Press - Journals","issue":"3","content-domain":{"domain":["direct.mit.edu"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pharmaceutical firms enjoy market exclusivity for new drugs from concurrent patent protection and exclusivity of the clinical trials data submitted for market approval. Patent invalidation during drug development renders data exclusivity the sole source of protection and shifts the period of market exclusivity. In instrumental variables regressions, we quantify the effect of a one-year reduction in expected market exclusivity on the likelihood of drug commercialization. The effect is largely driven by patent invalidations early in the drug development process and by the responses of large originators. We provide estimates of the responsiveness of R&amp;D investments to market exclusivity expectations.<\/jats:p>","DOI":"10.1162\/rest_a_00987","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T22:41:40Z","timestamp":1604097700000},"page":"571-586","update-policy":"https:\/\/doi.org\/10.1162\/mitpressjournals.corrections.policy","source":"Crossref","is-referenced-by-count":22,"title":["Patents, Data Exclusivity, and the Development of New Drugs"],"prefix":"10.1162","volume":"104","author":[{"given":"Fabian","family":"Gaessler","sequence":"first","affiliation":[{"name":"Max Planck Institute for Innovation and Competition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wagner","sequence":"additional","affiliation":[{"name":"European School of Management and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"281","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"issue":"4","key":"2022051222595649000_B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0124257","article-title":"An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile","volume":"10","author":"Abud","year":"2015","journal-title":"PLOS One"},{"issue":"3","key":"2022051222595649000_B2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1162\/0033553041502144","article-title":"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry","volume":"119","author":"Acemoglu","year":"2004","journal-title":"Quarterly Journal of Economics"},{"issue":"2","key":"2022051222595649000_B3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Market Watch: Estimating the Cost of New Drug Development: Is It Really $802 Million?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Affairs"},{"issue":"10","key":"2022051222595649000_B4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1287\/mnsc.1090.1055","article-title":"A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development","volume":"55","author":"Arora","year":"2009","journal-title":"Management Science"},{"key":"2022051222595649000_B5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1515\/9781400879762-024","article-title":"Economic Welfare and the Allocation of Resources for Invention","volume-title":"The Rate and Direction of Inventive Activity: Economic and Social Factors","author":"Arrow","year":"1962"},{"issue":"8","key":"2022051222595649000_B6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug Repositioning: Identifying and Developing New Uses for Existing Drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"key":"2022051222595649000_B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpubeco.2012.10.003","article-title":"Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development,","volume":"97","author":"Blume-Kohout","year":"2013","journal-title":"Journal of Public Economics"},{"issue":"4","key":"2022051222595649000_B8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/1756-2171.12157","article-title":"Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry","volume":"47","author":"Branstetter","year":"2016","journal-title":"RAND Journal of Economics"},{"key":"2022051222595649000_B9","article-title":"Starving (or Fattening) the Golden Goose? Generic Entry and the Incentives for Early-Stage Pharmaceutical Innovation","volume":"17011","author":"Branstetter","year":"2017","journal-title":"Hoover IP2 working paper"},{"issue":"7","key":"2022051222595649000_B10","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1257\/aer.20131176","article-title":"Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials","volume":"105","author":"Budish","year":"2015","journal-title":"American Economic Review"},{"key":"2022051222595649000_B11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1287\/mnsc.1060.0676","article-title":"Strategic Management of R&D Pipelines with Cospecialized Investments and Technology Markets,","volume":"53","author":"Chan","year":"2007","journal-title":"Management Science"},{"key":"2022051222595649000_B12","article-title":"Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not)","volume":"7552","author":"Cohen","year":"2000","journal-title":"NBER working paper"},{"key":"2022051222595649000_B13","article-title":"AIS Post-Grant Review and European Oppositions: Will They Work in Tandem, or Rather Pass Like Ships in the Night?","volume":"14","author":"De Corte","year":"2012","journal-title":"North Carolina Journal of Law and Technology"},{"issue":"1","key":"2022051222595649000_B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/dewb.12105","article-title":"Raising the Barriers to Access to Medicines in the Developing World: The Relentless Push for Data Exclusivity","volume":"17","author":"Diependaele","year":"2017","journal-title":"Developing World Bioethics"},{"key":"2022051222595649000_B15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs,","volume":"47","author":"DiMasi","year":"2016","journal-title":"Journal of Health Economics"},{"key":"2022051222595649000_B16","doi-asserted-by":"crossref","DOI":"10.1515\/9781400830176","volume-title":"Investment under Uncertainty","author":"Dixit","year":"1994"},{"key":"2022051222595649000_B17","article-title":"Pharmaceutical Profits and the Social Value of Innovation","volume":"20212","author":"Dranove","year":"2014","journal-title":"NBER working paper"},{"issue":"4","key":"2022051222595649000_B18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1756-2171.12113","article-title":"Market Size and Pharmaceutical Innovation","volume":"46","author":"Dubois","year":"2015","journal-title":"RAND Journal of Economics"},{"key":"2022051222595649000_B19","unstructured":"European Commission, \u201cPharmaceutical Sector Inquiry Report. Final Report\u201d (July8, 2009)."},{"key":"2022051222595649000_B20","unstructured":"European Commission \u201cStudy on the Legal Aspects of Supplementary Protection Certificates in the EU,\u201d final report (May 25, 2018)."},{"key":"2022051222595649000_B21","article-title":"Bargaining Failure and Freedom to Operate: Reevaluating the Effect of Patents on Cumulative Innovation","volume":"13969","author":"Gaessler","year":"2019","journal-title":"CEPR discussion paper"},{"issue":"1","key":"2022051222595649000_B22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/qje\/qju029","article-title":"Patents and Cumulative Innovation: Causal Evidence from the Courts","volume":"130","author":"Galasso","year":"2015","journal-title":"Quarterly Journal of Economics"},{"issue":"9","key":"2022051222595649000_B23","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1287\/mnsc.1070.0703","article-title":"Valuing R&D Projects in a Portfolio: Evidence from the Pharmaceutical Industry","volume":"53","author":"Girotra","year":"2007","journal-title":"Management Science"},{"issue":"Suppl. 2","key":"2022051222595649000_B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00019053-200422002-00003","article-title":"Are the Economics of Pharmaceutical Research and Development Changing? Productivity, Patents and Political Pressures","volume":"22","author":"Grabowski","year":"2004","journal-title":"PharmacoEconomics"},{"issue":"2","key":"2022051222595649000_B25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1377\/hlthaff.2014.1047","article-title":"The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation","volume":"34","author":"Grabowski","year":"2015","journal-title":"Health Affairs"},{"issue":"4","key":"2022051222595649000_B26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijindorg.2004.01.001","article-title":"Determinants of Opposition against EPO Patent Grants: The Case of Biotechnology and Pharmaceuticals","volume":"22","author":"Harhoff","year":"2004","journal-title":"International Journal of Industrial Organization"},{"issue":"3","key":"2022051222595649000_B27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1287\/mnsc.2015.2152","article-title":"Conflict Resolution, Public Goods and Patent Thickets","volume":"62","author":"Harhoff","year":"2016","journal-title":"Management Science"},{"issue":"12","key":"2022051222595649000_B28","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1287\/mnsc.1090.1069","article-title":"The Duration of Patent Examination at the European Patent Office","volume":"55","author":"Harhoff","year":"2009","journal-title":"Management Science"},{"issue":"2","key":"2022051222595649000_B29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jhealeco.2012.01.004","article-title":"Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals","volume":"31","author":"Hemphill","year":"2012","journal-title":"Journal of Health Economics"},{"issue":"5951","key":"2022051222595649000_B30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1126\/science.1176116","article-title":"Balancing Innovation and Access: Patent Challenges Tip the Scales","volume":"326","author":"Higgins","year":"2009","journal-title":"Science"},{"key":"2022051222595649000_B31","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9080-8","volume-title":"Project Selection under Uncertainty: Dynamically Allocating Resources to Maximize Value","author":"Kavadias","year":"2004"},{"issue":"1","key":"2022051222595649000_B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jeconom.2005.02.011","article-title":"Generalized Reduced Rank Tests Using the Singular Value Decomposition","volume":"133","author":"Kleibergen","year":"2006","journal-title":"Journal of Econometrics"},{"key":"2022051222595649000_B33","article-title":"Trials and Terminations: Learning from Competitors' R&D Failures","volume":"18-043","author":"Krieger","year":"2017","journal-title":"Harvard Business School working paper"},{"key":"2022051222595649000_B34","article-title":"Developing Novel Drugs","volume":"18-056","author":"Krieger","year":"2018","journal-title":"HBS working paper"},{"key":"2022051222595649000_B35","doi-asserted-by":"crossref","unstructured":"Kyle, M. K., and A. M.McGahan, \u201cInvestments in Pharmaceuticals before and after TRIPS,\u201d this review94:4 (2012) 1157\u20131172. 22835551","DOI":"10.1162\/REST_a_00214"},{"key":"2022051222595649000_B36","article-title":"The Myths of Data Exclusivity,","volume":"20","author":"Lietzan","year":"2016","journal-title":"Lewis and Clark Law Review"},{"issue":"15","key":"2022051222595649000_B37","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jama.2015.10872","article-title":"The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines","volume":"314","author":"Luo","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"2022051222595649000_B38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11151-018-9630-3","article-title":"The Impact of the Entry of Biosimilars: Evidence from Europe","volume":"53","author":"Morton","year":"2018","journal-title":"Review of Industrial Organization"},{"key":"2022051222595649000_B39","volume-title":"Invention, Growth and Welfare: A Theoretical Treatment of Technological Change","author":"Nordhaus","year":"1969"},{"issue":"3","key":"2022051222595649000_B40","first-page":"1110","article-title":"Irreversibility, Uncertainty, and Investment","volume":"29","author":"Pindyck","year":"1991","journal-title":"Journal of Economic Literature"},{"key":"2022051222595649000_B41","doi-asserted-by":"publisher","DOI":"10.2202\/1538-0653.1329","article-title":"Time In Purgatory: Examining the Grant Lag for U.S. Patent Applications","volume":"4","author":"Popp","year":"2004","journal-title":"Topics in Economic Analysis and Policy"},{"key":"2022051222595649000_B42","doi-asserted-by":"crossref","unstructured":"Qian, Y.\n          , \u201cDo National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978\u20132002,\u201d this review89:3 (2007) 436\u2013453.","DOI":"10.1162\/rest.89.3.436"},{"key":"2022051222595649000_B43","unstructured":"Rao, A.\n          , \u201cStrategic R&D Investment Decisions in the Pharmaceutical Industry,\u201d SSRN working paper (2018)."},{"issue":"2","key":"2022051222595649000_B44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1377\/hlthaff.25.2.313","article-title":"Developing Drugs for Developing Countries","volume":"25","author":"Ridley","year":"2006","journal-title":"Health Affairs"},{"key":"2022051222595649000_B45","article-title":"Unpatentable Drugs and the Standards of Patentability,","volume":"87","author":"Roin","year":"2008","journal-title":"Texas Law Review"},{"issue":"1","key":"2022051222595649000_B46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/13571510500519905","article-title":"Generic Competition in the US Pharmaceutical Industry","volume":"13","author":"Saha","year":"2006","journal-title":"International Journal of the Economics of Business"},{"key":"2022051222595649000_B47","unstructured":"Sanjuan J. R. , \u201cUS and EU Protection of Pharmaceutical Test Data,\u201d Consumer Project on Technology (2006)."},{"key":"2022051222595649000_B48","article-title":"The Pharmaceutical Industry","volume-title":"Handbook of Health Economics","author":"Scherer","year":"2000"},{"key":"2022051222595649000_B49","unstructured":"Schmoch, U.\n          , \u201cConcept of a Technology Classification for Country Comparisons,\u201d Final Report to the World Intellectual Property Organisation (2008)."},{"key":"2022051222595649000_B50","volume-title":"Innovation and Incentives","author":"Scotchmer","year":"2004"},{"issue":"5","key":"2022051222595649000_B51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.respol.2016.02.006","article-title":"What Do Patent-Based Measures Tell Us about Product Commercialization? Evidence from the Pharmaceutical Industry","volume":"45","author":"Wagner","year":"2016","journal-title":"Research Policy"},{"key":"2022051222595649000_B52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-economics-110216-100959","article-title":"How Do Patents Affect Research Investments?","volume":"9","author":"Williams","year":"2017","journal-title":"Annual Review of Economics"}],"container-title":["The Review of Economics and Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/direct.mit.edu\/rest\/article-pdf\/104\/3\/571\/2021999\/rest_a_00987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/direct.mit.edu\/rest\/article-pdf\/104\/3\/571\/2021999\/rest_a_00987.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T23:00:36Z","timestamp":1652396436000},"score":1,"resource":{"primary":{"URL":"https:\/\/direct.mit.edu\/rest\/article\/104\/3\/571\/97736\/Patents-Data-Exclusivity-and-the-Development-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,9]]},"published-print":{"date-parts":[[2022,5,9]]}},"URL":"https:\/\/doi.org\/10.1162\/rest_a_00987","relation":{},"ISSN":["0034-6535","1530-9142"],"issn-type":[{"value":"0034-6535","type":"print"},{"value":"1530-9142","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2022,5]]}}}